Technical Analysis for MATN - Mateon Therapeutics Inc

Grade Last Price % Change Price Change
grade A 0.24 -5.88% -0.0150
MATN closed down 5.88 percent on Tuesday, August 20, 2019, on 60 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical MATN trend table...

Date Alert Name Type % Chg
1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Stochastic Reached Overbought Strength 0.00%
Upper Bollinger Band Walk Strength 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
Pocket Pivot Bullish Swing Setup -5.88%
Reversal New Highs Setup Bullish Swing Setup -5.88%

Older signals for MATN ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Mateon Therapeutics, Inc., formerly OXiGENE, Inc., is a biopharmaceutical company. The Company is focused on the development of vascular disrupting agents (VDAs) for the treatment of cancer. The Company is engaged in developing two clinical stage investigational drugs: VDAs-CA4P and OXi4503. Its lead compound is CA4P, which is also known as combretastatin A4-phosphate, fosbretabulin tromethamine, fosbretabulin and ZYBRESTAT. VDAs selectively targets the vasculature of cancer tumors and obstructs a tumor's blood supply without disrupting the blood supply to normal tissues. VDAs are in a class of drugs called vascular targeted therapies (VTTs), which also includes anti-angiogenic agents (AAs). CA4P is a reversible tubulin binding agent that selectively targets the endothelial cells that make up the blood vessel walls in solid tumors. The Company is pursuing the development of a product candidate, OXi4503, which is a dual-mechanism VDA.
Medicine Medical Specialties Cancer Clinical Medicine Biopharmaceutical Treatment Of Cancer Solid Tumors Tumor Cancer Treatments Angiology Angiogenesis Angiogenesis Inhibitor
Is MATN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 0.3096
52 Week Low 0.05
Average Volume 15,101
200-Day Moving Average 0.1494
50-Day Moving Average 0.1984
20-Day Moving Average 0.2111
10-Day Moving Average 0.2201
Average True Range 0.0198
ADX 40.75
+DI 41.3582
-DI 12.3248
Chandelier Exit (Long, 3 ATRs ) 0.2006
Chandelier Exit (Short, 3 ATRs ) 0.2394
Upper Bollinger Band 0.2429
Lower Bollinger Band 0.1793
Percent B (%b) 0.95
BandWidth 30.127902
MACD Line 0.0096
MACD Signal Line 0.0066
MACD Histogram 0.0031
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.2625
Resistance 3 (R3) 0.2650 0.2600 0.2588
Resistance 2 (R2) 0.2600 0.2543 0.2588 0.2575
Resistance 1 (R1) 0.2500 0.2507 0.2475 0.2475 0.2562
Pivot Point 0.2450 0.2450 0.2438 0.2438 0.2450
Support 1 (S1) 0.2350 0.2393 0.2325 0.2325 0.2238
Support 2 (S2) 0.2300 0.2357 0.2288 0.2225
Support 3 (S3) 0.2200 0.2300 0.2213
Support 4 (S4) 0.2175